Physician profile
Michael Bruce Johnson
NPI 1134123813
$16,770.71
in general payments reported to CMS, 2019-2025
36 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $949 · 2021: $2,387 · 2022: $2,440 · 2023: $3,051 · 2024: $3,706 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,106 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,105.57 |
| Education | $113.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,900.65 | 2019-2025 | |
| Janssen Biotech, INC. | $2,124.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,428.30 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $815.12 | 2019-2025 | |
| Lilly USA, LLC | $461.89 | 2022-2025 | Omvoh, Zepbound |
| Celgene Corporation | $442.09 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $428.66 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $409.84 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $392.68 | 2024-2025 | Voquezna |
| Genzyme Corporation | $369.67 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $353.73 | 2020-2023 | |
| Gilead Sciences, INC. | $331.77 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $312.26 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $211.14 | 2020-2021 | |
| Amgen INC. | $207.24 | 2020-2023 | Avsola, Amjevita |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.41 | 2019-2024 | Xifaxan, Plenvu |
| Organon LLC | $195.57 | 2022-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $189.98 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $180.14 | 2019-2025 | Clenpiq |
| Redhill Biopharma INC. | $164.13 | 2021 | |
| Ironwood Pharmaceuticals, INC | $157.87 | 2021-2024 | Linzess |
| Evoke Pharma, INC. | $96.31 | 2021-2024 | Gimoti |
| Qol Medical, LLC | $77.98 | 2022-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $58.27 | 2025 | Iqirvo |
| Allergan, INC. | $52.95 | 2019-2020 | |
| Ardelyx, INC. | $40.32 | 2023 | Ibsrela |
| Madrigal Pharmaceuticals | $34.08 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $26.76 | 2022-2024 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $20.55 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $19.75 | 2025 | Givlaari |
| Celltrion USA INC. | $15.56 | 2025 | Vegzelma |
| Medtronic USA, INC. | $15.38 | 2020 | |
| Shire North American Group INC | $14.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2023 | Cyltezo |
| Echosens North America, INC. | $11.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,544.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.